GeNeuro S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Cost of Goods Sold (COGS) incl. D&A
65.00
43.40
31.80
43.10
-
Gross Income
65.00
43.40
31.80
43.10
-
SG&A Expense
3,788.30
5,986.70
7,452.70
18,551.30
22,119.70
EBIT
3,853.30
6,030.10
7,496.70
18,671.80
22,119.70
Unusual Expense
9.30
-
-
1,801.30
-
Non Operating Income/Expense
53.20
7,357.90
2,352.10
5,846.80
15,018.00
Interest Expense
138.40
10.50
6.80
7.10
-
Pretax Income
4,001.40
1,332.20
5,098.40
14,616.60
1,361.80
Income Tax
502.60
444.20
611.20
513.30
1,361.80
Consolidated Net Income
3,498.80
1,776.40
4,487.20
14,103.30
-
Net Income
3,498.80
1,776.40
4,487.20
14,103.30
-
Net Income After Extraordinaries
3,498.80
1,776.40
4,487.20
14,103.30
0.00
Net Income Available to Common
3,498.80
1,776.40
4,487.20
14,103.30
5,837.20
EPS (Basic)
0.24
0.12
0.31
1.02
0.40
Basic Shares Outstanding
14,658.10
14,658.10
14,658.10
13,867.00
-
EPS (Diluted)
0.24
0.12
0.31
1.01
-
Diluted Shares Outstanding
14,658.10
14,658.10
14,658.10
13,985.00
-
EBITDA
3,788.30
5,986.70
7,464.90
18,628.70
-
Other Operating Expense
-
-
12.20
77.40
-
Non-Operating Interest Income
34.20
14.90
53.00
16.80
-

About GeNeuro

View Profile
Address
3, Chemin du Pré-Fleuri
Plan-les-Ouates Geneve (Geneva) 1228
Switzerland
Employees -
Website http://www.geneuro.ch/fr/accueil
Updated 07/08/2019
GeNeuro SA engages in the research and development of pharmaceutical products. It offers GNbAC1, a therapeutic antibody that targets MSRV-Env. It also offers a drug for multiple sclerosis.